Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Net Income (2016 - 2025)

Historic Net Income for Niagen Bioscience (NAGE) over the last 16 years, with Q3 2025 value amounting to $4.6 million.

  • Niagen Bioscience's Net Income rose 14377.0% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.4 million, marking a year-over-year increase of 127569.02%. This contributed to the annual value of $8.5 million for FY2024, which is 27314.7% up from last year.
  • According to the latest figures from Q3 2025, Niagen Bioscience's Net Income is $4.6 million, which was up 14377.0% from $3.6 million recorded in Q2 2025.
  • Over the past 5 years, Niagen Bioscience's Net Income peaked at $7.2 million during Q4 2024, and registered a low of -$8.9 million during Q3 2021.
  • Over the past 5 years, Niagen Bioscience's median Net Income value was -$1.4 million (recorded in 2022), while the average stood at -$1.5 million.
  • Its Net Income has fluctuated over the past 5 years, first plummeted by 11010.68% in 2021, then soared by 2416000.0% in 2025.
  • Over the past 5 years, Niagen Bioscience's Net Income (Quarter) stood at -$5.3 million in 2021, then skyrocketed by 72.88% to -$1.4 million in 2022, then skyrocketed by 107.89% to $114000.0 in 2023, then skyrocketed by 6197.37% to $7.2 million in 2024, then crashed by 36.23% to $4.6 million in 2025.
  • Its last three reported values are $4.6 million in Q3 2025, $3.6 million for Q2 2025, and $5.1 million during Q1 2025.